Use of medications moderating hypokalemia, such as ACE inhibitors, ARBs, or MRAs, while greater in those with a prior MI or stroke compared with those without prior MI or stroke, was not different in those randomized to CTD compared with HCTZ over the course of the study. The gene discussed is ACE; the disease is Stroke.